The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm resulted in shares of the biotech rocketing higher – and the rest of the biotech sector went… Read More »Should Investors “Say Yes To Drugs” On Heels Of Biogen Approval?
When it comes to biotech plays, the author of today’s article advises that there are two investors should know: “The first is to buy stock… Read More »2 Biotech Plays To Know – And 1 Stock For Each Play Right Now
The small-cap biotech featured in today’s article develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries. As… Read More »“Powered By The Pandemic”: An Attractive Entry Point For This Small-Cap Biotech?
As a manufacturer of COVID-19 tests – and the top provider of COVID-19 testing in California – the company featured in today’s article has seen… Read More »Is This COVID-19 Test Manufacturer’s Spectacular Growth Story Nearing Its End – Or Entering The Next Chapter?
With a potential treatment for Alzheimer’s disease, a deal to co-develop a proven-effective COVID-19 vaccine for the U.S. market, and a platform of red-blood-cell-based cancer… Read More »Contraindicated: Why These 3 Biotech Stocks With Massive Gains Could Be Toxic For Portfolios
With several smaller drug and biotech companies still to report fourth-quarter earnings, today’s article highlights four which are expected to deliver earnings surprises in their… Read More »4 Drug/Biotech Stocks Set To Deliver Earnings Surprises
In the genome sequencing space, the stock highlighted in today’s article may not be the best stock – yet. As the author details, however, “when… Read More »This Genome Sequencing Stock’s Monster Run May Be Far From Over
“While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even… Read More »Biotech, Women’s Intimate Health & More: 5 Stocks Under $10 Offering Solid Alpha Potential
While the biotech sector has outperformed the broader market over the past 12 months, investing in this sector can be risky. As such, the author… Read More »Assessing The Best Biotech ETFs
“While volatility still permeates the broad market, one segment has seen a fairly consistent upward trend through the bulk of the year. That segment is,… Read More »The Tailwinds Behind Biotech – And How Both Traders And Investors Can Profit With ETFs